Opendata, web and dolomites

PRESTIGE-AF SIGNED

PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PRESTIGE-AF project word cloud

Explore the words cloud of the PRESTIGE-AF project. It provides you a very rough idea of what is the project "PRESTIGE-AF" about.

mri    subtype    stroke    tools    unmet    rct    trials    primary    therapy    countries    clinical    generally    economic    mortality    antiplatelet    quality    oac    disability    biomarkers    attitudes    662    ischemic    20    inferior    generalizability    societal    genetics    integrating    personalize    packages    modeling    enrollment    settings    prevented    trial    intracerebral    powered    anticoagulants    adherence    patient    relevance    generate    balance    antithrombotic    prospective    prevention    outcome    population    recruit    expectancy    baseline    model    replication    co    imbalances    risk    centered    outputs    randomized    recurrence    causing    tailor    hemorrhage    perform    atrial    biological    benefits    severe    health    sequential    first    endpoint    explore    regarding    strokes    size    reduces    sufficiently    oral    recurrent    life    blinded    af    dilemma    direct    blood    patients    desirable    gender    centers    prestige    data    individualized    survivors    public    tool    bleeding    fibrillation    personalized    versus    prediction    superior    uncertain    multidimensional    follow    ich    estimate    individual    hierarchical   

Project "PRESTIGE-AF" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 6˙958˙896 €
 EC max contribution 6˙958˙896 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2022-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 3˙332˙520.00
2    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 1˙019˙373.00
3    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) participant 468˙398.00
4    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 447˙700.00
5    MEDIZINISCHE UNIVERSITAT GRAZ AT (GRAZ) participant 343˙300.00
6    KING'S COLLEGE LONDON UK (LONDON) participant 340˙000.00
7    UNIVERSITE DE BORDEAUX FR (BORDEAUX) participant 330˙609.00
8    JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG DE (WUERZBURG) participant 283˙372.00
9    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 116˙562.00
10    AZIENDA OSPEDALIERA DI PERUGIA IT (PERUGIA) participant 115˙012.00
11    REGION NORDJYLLAND (NORTH DENMARK REGION) DK (AALBORG) participant 112˙500.00
12    STROKE ALLIANCE FOR EUROPE BE (BRUSSELS) participant 45˙000.00
13    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 4˙547.00

Map

 Project objective

Intracerebral hemorrhage (ICH) is a severe stroke subtype causing higher mortality and more disability than other strokes. 20% of ICH survivors have atrial fibrillation (AF), a major cause of ischemic stroke (IS). While IS in AF patients is generally prevented by oral anticoagulants (OAC), their use in ICH survivors is uncertain due to increased bleeding risk. No evidence from randomized controlled trials (RCT) is available addressing this dilemma. Personalized risk prediction is desirable to balance benefits of OAC against bleeding risk for individualized prevention.

Objectives: (1) To perform the first sufficiently powered RCT in ICH survivors with AF testing if direct OAC are superior for IS prevention and non-inferior regarding ICH recurrence versus antiplatelet or no antithrombotic therapy (2) To personalize antithrombotic prevention by multidimensional risk modeling (3) To estimate population impact of trial outputs on health economic consequences and generalizability to European population (4) To explore patient-centered aspects including adherence, attitudes towards antithrombotic therapy and gender imbalances in trial enrollment.

Methods: Prospective, open RCT with blinded outcome assessment. Hierarchical sequential testing of co-primary endpoint IS and recurrent ICH. Sample size: 662 patients. RCT will recruit in 70 centers in 6 countries over 2 years with 2 year follow-up. Clinical characteristics, MRI, blood-biomarkers and genetics will be characterized at baseline to model a new personalized risk prediction tool.

Relevance for work program: PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in ICH patients with AF. Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. Work packages integrating biological data will generate new tools to tailor prevention. Modeling of economic and societal consequences and replication in real-life settings will estimate population impact.

 Deliverables

List of deliverables.
First study subject approvals package Documents, reports 2020-03-24 00:29:29
Educational video on“Sample Collection Methods for Biomarker Studies” Websites, patent fillings, videos etc. 2020-03-24 00:29:29
PRESTIGE-AF “Dissemination Package” Other 2020-03-24 00:29:29
Launch of website and social media accounts Websites, patent fillings, videos etc. 2020-03-24 00:29:29
Dissemination & Communication Plan Documents, reports 2020-03-24 00:29:29

Take a look to the deliverables list in detail:  detailed list of PRESTIGE-AF deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRESTIGE-AF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRESTIGE-AF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

SHIGETECVAX (2019)

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More